McGeer & McGeer, “The future use of complement inhibitors for the treatment of neurological diseases.” Drugs 55(6):739-46, 1998. |
Morgan et al., “The role of complement in disorders of the nervous system.” Immunopharmacology 38(1-2):43-50, 1997. |
Naka et al., “Complement activation as a cause for primary graft failure in an isogeneic rat model of hypothermic lung preservation and transplantation.” Transplantation 64(9):1248-55, 1997. |
Shen et al., “Characterization of neuronal cell death induced by complement activation.” Brain Res Brain Res Protoc 1(2):186-94, 1997. |
Shen et al., “Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain.” Brain Res 769(2):391-5, 1997. |
Tao et al., “Monomeric bovine IgG2 is a potent stimulus for bovine neutrophils.” J Leukoc Biol, 58: 203-8, 1995. |
Terai et al., “Neurons express proteins of the classical complement pathway in Alzheimer disease.” Brain Res 769(2):385-90, 1997. |
Gajewski et al, Tumor rejection requires a CTLA4 Ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7 for active tumor immunization. 156(8) J. Immunol. 2909-17 (1996). |
Stabila et al., Cell surface expression of a human IgG Fc chimera activates macrophages through Fc receptors. 16(13) Nat Biotechnol. 1357-60 (1998). |
Yu et al., The role of B7-CD28 co-stimulation in tumor rejection. 10(6) Int. Immunol. 791-7 (1998). |